Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
CCXI [NASD]
ChemoCentryx, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-0.67 Insider Own3.80% Shs Outstand68.92M Perf Week1.59%
Market Cap4.56B Forward P/E- EPS next Y-1.48 Insider Trans-16.69% Shs Float52.91M Perf Month7.82%
Income-41.00M PEG- EPS next Q-0.34 Inst Own81.80% Short Float9.95% Perf Quarter23.75%
Sales70.60M P/S64.53 EPS this Y-28.00% Inst Trans0.64% Short Ratio9.30 Perf Half Y20.37%
Book/sh5.87 P/B10.97 EPS next Y-98.60% ROA-11.10% Target Price80.63 Perf Year58.08%
Cash/sh6.66 P/C9.66 EPS next 5Y- ROE-17.20% 52W Range30.72 - 65.43 Perf YTD4.01%
Dividend- P/FCF- EPS past 5Y2.10% ROI-68.00% 52W High-1.57% Beta1.39
Dividend %- Quick Ratio10.10 Sales past 5Y- Gross Margin- 52W Low109.64% ATR3.09
Employees82 Current Ratio10.10 Sales Q/Q-51.90% Oper. Margin-59.20% RSI (14)59.91 Volatility5.53% 5.00%
OptionableYes Debt/Eq0.06 EPS Q/Q-58.00% Profit Margin-58.10% Rel Volume1.00 Prev Close63.28
ShortableYes LT Debt/Eq0.05 EarningsNov 09 AMC Payout- Avg Volume566.02K Price64.40
Recom1.60 SMA205.14% SMA508.22% SMA20015.30% Volume564,468 Change1.77%
Oct-29-20Downgrade JP Morgan Overweight → Neutral $63 → $60
Jun-17-20Initiated BTIG Research Buy $70
May-27-20Initiated Wells Fargo Overweight $79
May-12-20Reiterated H.C. Wainwright Buy $60 → $69
Jan-24-20Reiterated H.C. Wainwright Buy $40 → $60
Nov-26-19Reiterated Piper Jaffray Overweight $17 → $54
Nov-26-19Reiterated H.C. Wainwright Buy $23 → $40
Mar-27-19Upgrade B. Riley FBR Neutral → Buy $12.50 → $22
Feb-11-19Initiated Piper Jaffray Overweight $20
Sep-07-18Initiated B. Riley FBR Neutral $12.50
Aug-14-18Downgrade JP Morgan Overweight → Neutral
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Initiated H.C. Wainwright Buy $20
Feb-21-17Initiated JMP Securities Mkt Outperform
May-18-15Upgrade JP Morgan Neutral → Overweight
May-20-13Reiterated Stifel Buy $16 → $20
Nov-14-12Initiated Stifel Nicolaus Buy $16
Jan-06-21 08:30AM  
ChemoCentryx to Participate in Two Upcoming Investor Conferences
GlobeNewswire
Dec-22-20 11:11PM  
What Does The Future Hold For ChemoCentryx, Inc. (NASDAQ:CCXI)? These Analysts Have Been Cutting Their Estimates
Simply Wall St.
10:22AM  
ChemoCentryx (CCXI) Reports Positive Top-Line Rare Disease Data
Zacks
07:45AM  
The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes
Benzinga
Dec-21-20 04:05PM  
ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
GlobeNewswire
Dec-14-20 08:25AM  
Monopoly Regulators to Probe Tencents DouYu-Huya Merger and Punish China Literature and Alibaba
Variety
Dec-09-20 11:30AM  
Why Is ChemoCentryx (CCXI) Up 2% Since Last Earnings Report?
Zacks
Dec-02-20 11:37PM  
Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 27%?
Simply Wall St.
Nov-19-20 08:30AM  
ChemoCentryx to Present at Two Upcoming Investor Conferences
GlobeNewswire
Nov-10-20 10:43AM  
ChemoCentryx (CCXI) Reports Wider-Than-Expected Q3 Loss
Zacks
Nov-09-20 11:31PM  
ChemoCentryx Inc (CCXI) Q3 2020 Earnings Call Transcript
Motley Fool +5.44%
06:05PM  
ChemoCentryx (CCXI) Reports Q3 Loss, Lags Revenue Estimates
Zacks
05:01PM  
Recap: ChemoCentryx Q3 Earnings
Benzinga
04:05PM  
ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights
GlobeNewswire
03:15PM  
ChemoCentryx, Inc. to Host Earnings Call
ACCESSWIRE
Nov-06-20 10:15AM  
Earnings Outlook For ChemoCentryx
Benzinga
08:30AM  
ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis
GlobeNewswire
Nov-03-20 08:30AM  
ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
GlobeNewswire
Nov-02-20 08:30AM  
ChemoCentryx to Hold Third Quarter 2020 Financial Results Conference Call on Monday, November 9, 2020
GlobeNewswire
Oct-28-20 04:01PM  
ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)
GlobeNewswire
Oct-26-20 12:31PM  
Analysts Estimate ChemoCentryx (CCXI) to Report a Decline in Earnings: What to Look Out for
Zacks -9.52%
Oct-19-20 08:03AM  
Despite Lacking Profits ChemoCentryx (NASDAQ:CCXI) Seems To Be On Top Of Its Debt
Simply Wall St. -5.60%
Sep-18-20 10:56AM  
ChemoCentryx's NDA for Autoimmune Disease Drug Accepted by FDA
Zacks +5.21%
Sep-17-20 08:30AM  
ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis
GlobeNewswire
Sep-15-20 12:47AM  
Hedge Funds Arent Done Buying ChemoCentryx Inc (CCXI)
Insider Monkey
Sep-08-20 08:30AM  
ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
GlobeNewswire
Sep-04-20 08:45AM  
Imagine Holding ChemoCentryx (NASDAQ:CCXI) Shares While The Price Zoomed 652% Higher
Simply Wall St.
Aug-11-20 04:31PM  
ChemoCentryx Inc (CCXI) Q2 2020 Earnings Call Transcript
Motley Fool
10:00AM  
Tencents China Literature Crashes to $465 Million Loss
Variety
Aug-10-20 05:45PM  
ChemoCentryx (CCXI) Q2 Earnings and Revenues Surpass Estimates
Zacks
04:05PM  
ChemoCentryx Reports Second Quarter 2020 Financial Results and Recent Highlights
GlobeNewswire
Aug-04-20 08:30AM  
ChemoCentryx to Present at Two Upcoming Investor Conferences
GlobeNewswire
Aug-03-20 08:30AM  
ChemoCentryx to Hold Second Quarter 2020 Financial Results Conference Call on Monday, August 10, 2020
GlobeNewswire
Jul-27-20 12:31PM  
Earnings Preview: ChemoCentryx (CCXI) Q2 Earnings Expected to Decline
Zacks
Jul-21-20 06:37AM  
How Much is ChemoCentryx's (NASDAQ:CCXI) CEO Getting Paid?
Simply Wall St.
Jul-17-20 11:02AM  
Insiders Roundup: Mastercard, ChemoCentryx
GuruFocus.com
Jul-13-20 10:43AM  
Did Hedge Funds Make The Right Call On ChemoCentryx Inc (CCXI) ?
Insider Monkey -5.24%
Jul-10-20 11:11AM  
Insiders Roundup: Mastercard, Eli Lilly
GuruFocus.com
Jul-09-20 08:30AM  
ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis
GlobeNewswire
Jul-07-20 11:14AM  
3 Perfect 10 Healthcare Stocks That Have Plenty of Growth on Tap
TipRanks
08:50AM  
Are Options Traders Betting on a Big Move in ChemoCentryx (CCXI) Stock?
Zacks
Jun-29-20 12:53PM  
Top Small Cap Stocks for July 2020
Investopedia
Jun-24-20 08:30AM  
ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
GlobeNewswire
Jun-15-20 10:34PM  
Edited Transcript of CCXI.OQ earnings conference call or presentation 11-May-20 9:00pm GMT
Thomson Reuters StreetEvents
04:05PM  
ChemoCentryx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire
Jun-12-20 09:49AM  
Hedge Funds Have Never Been This Bullish On ChemoCentryx Inc (CCXI)
Insider Monkey +12.11%
Jun-10-20 09:33PM  
ChemoCentryx Prices Public Offering of Common Stock
GlobeNewswire
04:08PM  
ChemoCentryx Announces Proposed Public Offering of Common Stock
GlobeNewswire
Jun-03-20 07:30AM  
ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Highlighted in Oral Plenary Presentations at EULAR and ERA-EDTA Congresses
GlobeNewswire
May-18-20 08:30AM  
ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
GlobeNewswire +8.72%
May-16-20 10:49AM  
Analysts Have Just Cut Their ChemoCentryx, Inc. (NASDAQ:CCXI) Revenue Estimates By 11%
Simply Wall St.
May-14-20 06:53AM  
ChemoCentryx, Inc. (NASDAQ:CCXI) Just Reported And Analysts Have Been Cutting Their Estimates
Simply Wall St.
May-12-20 01:30PM  
ChemoCentryx Inc (CCXI) Q1 2020 Earnings Call Transcript
Motley Fool
May-11-20 07:55PM  
ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates
Zacks
04:05PM  
ChemoCentryx Reports First Quarter 2020 Financial Results and Recent Highlights
GlobeNewswire
07:00AM  
Is There An Opportunity With ChemoCentryx, Inc.'s (NASDAQ:CCXI) 47% Undervaluation?
Simply Wall St.
May-04-20 08:30AM  
ChemoCentryx to Hold First Quarter 2020 Financial Results Conference Call on Monday, May 11, 2020
GlobeNewswire +6.27%
Apr-27-20 12:31PM  
Analysts Estimate ChemoCentryx (CCXI) to Report a Decline in Earnings: What to Look Out for
Zacks
Apr-22-20 12:00PM  
Here's Why Momentum Investors Will Love ChemoCentryx (CCXI)
Zacks
Apr-07-20 12:00PM  
ChemoCentryx (CCXI) Upgraded to Buy: What Does It Mean for the Stock?
Zacks
Apr-05-20 01:17AM  
Edited Transcript of CCXI earnings conference call or presentation 10-Mar-20 9:00pm GMT
Thomson Reuters StreetEvents
Mar-31-20 04:52PM  
5 Guru Stocks That Beat the Market
GuruFocus.com
Mar-16-20 09:47AM  
Why ChemoCentryx (CCXI) Stock Might be a Great Pick
Zacks -22.52%
Mar-12-20 07:00AM  
ChemoCentryx, Inc. Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
Simply Wall St. -5.90%
Mar-10-20 05:25PM  
ChemoCentryx (CCXI) Reports Q4 Loss, Tops Revenue Estimates
Zacks
04:05PM  
ChemoCentryx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
GlobeNewswire
03:00PM  
ChemoCentryx, Inc. to Host Earnings Call
ACCESSWIRE
Mar-03-20 08:30AM  
ChemoCentryx to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, March 10, 2020
GlobeNewswire
Mar-02-20 12:30PM  
ChemoCentryx (CCXI) Expected to Beat Earnings Estimates: Should You Buy?
Zacks
Feb-19-20 08:30AM  
ChemoCentryx to Present at the 9th Annual SVB Leerink Global Healthcare Conference
GlobeNewswire
Jan-10-20 06:00PM  
Biotechs punch up talking points leading into big Union Square conference
American City Business Journals
05:01AM  
Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 423% Share Price Gain?
Simply Wall St.
Jan-09-20 08:30AM  
ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital
GlobeNewswire
Jan-08-20 08:30AM  
ChemoCentryx to Present at the 38th Annual JP Morgan Healthcare Conference
GlobeNewswire
Dec-11-19 03:58PM  
Hedge Funds Dropped The Ball On ChemoCentryx Inc (CCXI)
Insider Monkey
Dec-01-19 09:30AM  
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
Benzinga
Nov-29-19 11:24AM  
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
Zacks
Nov-28-19 09:00AM  
ChemoCentryx (CCXI) Upgraded to Buy: What Does It Mean for the Stock?
Zacks
Nov-27-19 10:15AM  
Company News For Nov 27, 2019
Zacks
10:09AM  
Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More
Zacks
08:52AM  
ChemoCentryx Up on Encouraging Rare Disease Candidate Data
Zacks
07:26AM  
The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen
Benzinga
07:23AM  
Drug maker ChemoCentryx shares rocket on blockbuster potential in rare autoimmune disease
MarketWatch
Nov-26-19 02:03PM  
ChemoCentryx (CCXI) Stock Could Hit $40, Says Analyst
TipRanks +281.27%
10:07AM  
These stocks and ETFs will help investors survive a not great year, says top Wall Street strategist
MarketWatch
08:42AM  
Benzinga Pro's Top 5 Stocks To Watch For Tues., Nov. 26, 2019: BBY, CCXI, PANW, DLTR, DE
Benzinga
08:30AM  
ChemoCentryx to Present at the 31st Annual Piper Jaffray Healthcare Conference
GlobeNewswire
08:14AM  
Dow Jones Futures: Palo Alto Networks Dives, Nutanix Soars; This Biotech Quadruples
Investor's Business Daily
08:06AM  
The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug
Benzinga
07:00AM  
Market Morning: CBD Warning, Chemocentryx Win, Huge Tory Majority, Amazon Injuries
Market Exclusive
01:00AM  
VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopans Superiority Over Standard of Care in ANCA Associated Vasculitis
TEST Business Wire Releases
01:00AM  
VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopans Superiority Over Standard of Care in ANCA Associated Vasculitis
Business Wire
Nov-25-19 06:11PM  
ChemoCentryx stock quadruples after 'transformational' vasculitis study
MarketWatch
04:05PM  
ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopans Superiority Over Standard of Care in ANCA-Associated Vasculitis
GlobeNewswire
08:54AM  
Are Options Traders Betting on a Big Move in ChemoCentryx (CCXI) Stock?
Zacks
Nov-20-19 05:32PM  
Plans filed for massive biotech campus in San Carlos
American City Business Journals
Nov-17-19 02:41AM  
Edited Transcript of CCXI earnings conference call or presentation 4-Nov-19 10:00pm GMT
Thomson Reuters StreetEvents
Nov-11-19 08:33AM  
How Should Investors React To ChemoCentryx, Inc.'s (NASDAQ:CCXI) CEO Pay?
Simply Wall St.
Nov-05-19 08:30AM  
Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platform in Treatment of Complement 3 Glomerulopathy (C3G) and Focal Segmental Glomerulosclerosis (FSGS)
GlobeNewswire +6.84%
Nov-04-19 06:45PM  
ChemoCentryx (CCXI) Reports Q3 Loss, Tops Revenue Estimates
Zacks
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schall Thomas J.President and CEOJan 01Option Exercise0.0087,89902,356,456Jan 07 08:40 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 01Option Exercise0.0030,3330135,263Jan 07 08:32 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 01Option Exercise0.0021,100097,347Jan 07 08:26 PM
Edwards Thomas A.DirectorDec 28Sale61.5010,782663,093141,357Dec 29 06:58 PM
Edwards Thomas A.DirectorDec 24Sale61.1814,218869,904152,139Dec 29 06:58 PM
Kwan Pui SanPrincipal Acctg OfficerDec 15Option Exercise10.0742,593428,94345,825Dec 16 07:46 PM
Schall Thomas J.President and CEODec 15Option Exercise14.3117,619252,1282,286,176Dec 16 07:51 PM
Schall Thomas J.President and CEODec 15Sale65.0117,6191,145,4502,268,557Dec 16 07:51 PM
Kwan Pui SanPrincipal Acctg OfficerDec 15Sale65.0642,5932,771,2373,232Dec 16 07:46 PM
Kwan Pui SanPrincipal Acctg OfficerDec 14Option Exercise7.058,95763,15812,189Dec 16 07:46 PM
Schall Thomas J.President and CEODec 14Option Exercise14.3111,153159,5992,279,710Dec 16 07:51 PM
Schall Thomas J.President and CEODec 14Sale65.0311,153725,2462,268,557Dec 16 07:51 PM
Kwan Pui SanPrincipal Acctg OfficerDec 14Sale65.028,957582,3983,232Dec 16 07:46 PM
Vifor (International) Ltd10% OwnerAug 03Sale53.9349,2582,656,6559,194,085Aug 03 07:10 PM
Vifor (International) Ltd10% OwnerJul 31Sale52.3940,4022,116,8259,243,343Aug 03 07:10 PM
Vifor (International) Ltd10% OwnerJul 30Sale54.6048,0812,625,3309,283,745Aug 03 07:10 PM
Vifor (International) Ltd10% OwnerJul 29Sale52.5888,0124,627,4799,331,826Jul 29 07:55 PM
Vifor (International) Ltd10% OwnerJul 28Sale53.5140,1602,149,1179,419,838Jul 29 07:55 PM
Vifor (International) Ltd10% OwnerJul 27Sale53.3234,2361,825,4769,459,998Jul 29 07:55 PM
Vifor (International) Ltd10% OwnerJul 24Sale52.5426,0501,368,7379,494,234Jul 24 07:53 PM
Vifor (International) Ltd10% OwnerJul 23Sale54.1534,5551,871,2979,520,284Jul 24 07:53 PM
Vifor (International) Ltd10% OwnerJul 22Sale55.5872,4694,027,8689,554,839Jul 24 07:53 PM
Vifor (International) Ltd10% OwnerJul 21Sale55.5087,5294,857,6329,627,308Jul 21 06:32 PM
Vifor (International) Ltd10% OwnerJul 20Sale56.0354,5983,059,0539,714,837Jul 21 06:32 PM
Vifor (International) Ltd10% OwnerJul 17Sale55.8647,8902,675,1059,769,435Jul 21 06:32 PM
Vifor (International) Ltd10% OwnerJul 16Sale56.9673,5004,186,7419,817,325Jul 16 08:00 PM
Vifor (International) Ltd10% OwnerJul 15Sale59.2286,2985,110,9719,890,825Jul 16 08:00 PM
Vifor (International) Ltd10% OwnerJul 14Sale58.08100,0005,808,3189,977,123Jul 16 08:00 PM
Vifor (International) Ltd10% OwnerJul 13Sale58.15100,0005,815,02710,077,123Jul 13 07:18 PM
Vifor (International) Ltd10% OwnerJul 10Sale59.9245,8442,747,17210,177,123Jul 13 07:18 PM
Vifor (International) Ltd10% OwnerJul 09Sale59.91100,0005,990,52110,222,967Jul 13 07:18 PM
Vifor (International) Ltd10% OwnerJul 08Sale59.95100,0005,994,74510,322,967Jul 08 08:39 PM
Vifor (International) Ltd10% OwnerJul 07Sale59.2179,3874,700,83810,422,967Jul 08 08:39 PM
Vifor (International) Ltd10% OwnerJul 06Sale58.4486,6905,066,12010,502,354Jul 08 08:39 PM
Vifor (International) Ltd10% OwnerJul 02Sale57.4787,7815,044,43410,589,044Jul 07 06:57 PM
Schall Thomas J.President and CEOJun 15Option Exercise14.312,00028,6202,270,557Jun 16 08:20 PM
Schall Thomas J.President and CEOJun 15Sale65.042,000130,0902,268,557Jun 16 08:20 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJun 12Option Exercise10.8633,541364,255109,788Jun 16 08:02 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 12Option Exercise9.3250,000466,100141,317Jun 16 08:08 PM
Schall Thomas J.President and CEOJun 12Option Exercise14.3188,7531,270,0552,357,310Jun 16 08:20 PM
Schall Thomas J.President and CEOJun 12Sale65.0888,7535,775,8772,268,557Jun 16 08:20 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 12Sale64.5850,0003,229,03591,317Jun 16 08:08 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJun 12Sale65.1033,5412,183,51976,247Jun 16 08:02 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 03Option Exercise5.3110,75057,059104,930Jun 05 07:11 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 26Option Exercise6.6219,612129,83195,859May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 26Sale60.3419,6121,183,42376,247May 26 09:04 PM
Tyree James LDirectorMay 23Option Exercise0.007,724013,069May 26 08:59 PM
Parker Geoffrey M.DirectorMay 23Option Exercise0.007,7240111,913May 26 08:55 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 22Option Exercise6.6240,867270,540117,114May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 22Sale60.0640,8672,454,52576,247May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 21Option Exercise6.622,80018,53679,047May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 21Sale60.002,800167,98676,247May 26 09:04 PM
Schall Thomas J.President and CEOMay 12Option Exercise14.3135,865513,2282,304,422May 12 07:50 PM
Schall Thomas J.President and CEOMay 12Sale57.7535,8652,071,1002,268,557May 12 07:50 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 11Option Exercise3.5734,222122,173110,469May 12 07:45 PM
Schall Thomas J.President and CEOMay 11Option Exercise14.3170,6081,010,4002,339,165May 12 07:50 PM
Schall Thomas J.President and CEOMay 11Sale55.5170,6083,919,7312,268,557May 12 07:50 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 11Sale55.1134,2221,886,13576,247May 12 07:45 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 08Option Exercise3.574,31215,39480,559May 12 07:45 PM
Schall Thomas J.President and CEOMay 08Option Exercise14.314,20160,1162,272,758May 12 07:50 PM
Schall Thomas J.President and CEOMay 08Sale55.014,201231,1152,268,557May 12 07:50 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 08Sale50.014,312215,63976,247May 12 07:45 PM
Schall Thomas J.President and CEOMay 05Option Exercise14.318,851126,6582,277,408May 07 08:11 PM
KANAYA SUSAN MEVP, CFO and Sec.May 05Option Exercise8.1920,123164,807111,440May 06 08:19 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 05Option Exercise3.578,86031,63085,107May 07 07:59 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 05Sale55.018,860487,34576,247May 07 07:59 PM
KANAYA SUSAN MEVP, CFO and Sec.May 05Sale54.7320,1231,101,23791,317May 06 08:19 PM
Schall Thomas J.President and CEOMay 05Sale55.018,851486,8512,268,557May 07 08:11 PM
KANAYA SUSAN MEVP, CFO and Sec.May 04Option Exercise8.1954,877449,443146,194May 06 08:19 PM
KANAYA SUSAN MEVP, CFO and Sec.May 04Sale54.5754,8772,994,81991,317May 06 08:19 PM
Jain RitaDirectorMar 27Option Exercise0.005,251012,975Mar 31 07:10 PM
Parker Geoffrey M.DirectorMar 23Sale36.7030,0001,101,04949,600Mar 25 06:42 PM
Schall Thomas J.President and CEOMar 04Option Exercise14.3140,844584,4782,309,401Mar 05 07:03 PM
Schall Thomas J.President and CEOMar 04Sale50.3540,8442,056,6912,268,557Mar 05 07:03 PM
Schall Thomas J.President and CEOFeb 20Option Exercise14.3115,341219,5302,283,898Feb 21 07:24 PM
Schall Thomas J.President and CEOFeb 20Sale50.2115,341770,2962,268,557Feb 21 07:24 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 19Option Exercise8.1942,631349,148118,878Feb 21 07:05 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 19Option Exercise10.8624,200262,812118,380Feb 21 07:15 PM
Schall Thomas J.President and CEOFeb 19Option Exercise14.3163,340906,3952,331,897Feb 21 07:24 PM
Schall Thomas J.President and CEOFeb 19Sale50.5063,3403,198,5142,268,557Feb 21 07:24 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 19Sale50.1324,2001,213,22194,180Feb 21 07:15 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 19Sale50.3642,6312,146,69876,247Feb 21 07:05 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 13Option Exercise9.7645,300442,029139,480Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 13Sale49.6145,3002,247,14794,180Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 12Option Exercise9.692,50024,21396,680Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 12Sale49.512,500123,77694,180Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 11Option Exercise10.683,00032,04697,180Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 11Sale49.503,000148,51094,180Feb 13 08:00 PM
Kwan Pui SanPrincipal Acctg OfficerFeb 11Sale49.1518,941930,888493Feb 13 07:50 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 06Option Exercise8.1936,850301,802113,097Feb 10 07:53 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 06Sale47.3136,8501,743,34076,247Feb 10 07:53 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 05Option Exercise8.1913,150107,69989,397Feb 05 08:02 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 05Sale47.0313,150618,45176,427Feb 05 08:02 PM
Schall Thomas J.President and CEOFeb 04Option Exercise14.31119,5251,710,4032,388,082Feb 06 06:51 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 04Option Exercise14.3199,6171,425,519193,797Feb 05 08:32 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 04Sale45.1099,6174,492,22994,180Feb 05 08:32 PM
Schall Thomas J.President and CEOFeb 04Sale45.18119,5255,400,7012,268,557Feb 06 06:51 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 03Option Exercise8.1948,471396,977124,718Feb 05 08:02 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 03Option Exercise14.313,83754,90798,017Feb 05 08:32 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 03Sale44.913,837172,31794,180Feb 05 08:32 PM
open in yahoo | open in reuters | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.